Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Verrica Pharmaceuticals (VRCA) Return on Sales (2021 - 2025)

Verrica Pharmaceuticals (VRCA) has 5 years of Return on Sales data on record, last reported at 1.63% in Q4 2025.

  • For Q4 2025, Return on Sales fell 584.0% year-over-year to 1.63%; the TTM value through Dec 2025 reached 0.53%, up 924.0%, while the annual FY2025 figure was 0.53%, 924.0% up from the prior year.
  • Return on Sales reached 1.63% in Q4 2025 per VRCA's latest filing, down from 0.02% in the prior quarter.
  • Across five years, Return on Sales topped out at 4.21% in Q4 2024 and bottomed at 178.08% in Q1 2023.
  • Average Return on Sales over 5 years is 24.3%, with a median of 4.31% recorded in 2024.
  • Peak YoY movement for Return on Sales: plummeted -15843bps in 2023, then skyrocketed 17277bps in 2024.
  • A 5-year view of Return on Sales shows it stood at 2.92% in 2021, then plummeted by -2852bps to 86.29% in 2022, then surged by 86bps to 12.4% in 2023, then skyrocketed by 134bps to 4.21% in 2024, then plummeted by -139bps to 1.63% in 2025.
  • Per Business Quant database, its latest 3 readings for Return on Sales were 1.63% in Q4 2025, 0.02% in Q3 2025, and 0.03% in Q2 2025.